SCHEMBL692337

SCHEMBL692337

[CH2]C(C)OCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56720 0.78
SCHEMBL766382 0.76
SCHEMBL21858258 0.76
SCHEMBL1513790 0.76
SCHEMBL2600786 0.74 TSHR (0.38)
SCHEMBL17489116 0.74 TSHR (0.38)
SCHEMBL2358428 0.74
SCHEMBL8400578 0.74 TSHR (0.38)
SCHEMBL4219834 0.74
SCHEMBL6962867 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3487481-A1 COMPOSITIONS COMPRISING A POLYSACCHARIDE MATRIX FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS Jointherapeutics S.r.l. (IT) 2019-05-29 EP claimed
EP-3364947-A1 AQUEOUS COMPOSITION COMPRISING DANTROLENE B. Braun Melsungen AG (DE) 2018-08-29 EP claimed
WO-2018015364-A1 COMPOSITIONS COMPRISING A POLYSACCHARIDE MATRIX FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS JOINTHERAPEUTICS S.R.L. (IT) 2018-01-25 WO claimed
WO-2017067980-A1 AQUEOUS COMPOSITION COMPRISING DANTROLENE B. BRAUN MELSUNGEN AG (DE) 2017-04-27 WO claimed
EP-3621963-B1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS REMYND N V (BE) 2024-01-24 EP disclosed
WO-2023241799-A1 FLAVANOLS FOR USE IN THE TREATMENT OF RETROVIRAL INFECTIONS Université Libre de Bruxelles (BE) 2023-12-21 WO disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
EP-3180003-B1 PKC-EPSILON INHIBITORS UNIV CALIFORNIA (US) 2022-01-12 EP disclosed
EP-3621963-A1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS Remynd N.V. (BE) 2020-03-18 EP disclosed
WO-2018206760-A1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS REMYND N.V. (BE) 2018-11-15 WO disclosed
CN-107964013-A Antifungal agent 詹森药业有限公司 2018-04-27 CN disclosed
CN-103228659-B Benzene derivative substituted 5, 6-dihydro-4H-pyrrolo [1,2-A ] [1,4] benzodiazepine and 6H-pyrrolo [1,2-A ] [1,4] benzodiazepine antifungal agent 詹森药业有限公司 2017-11-24 CN disclosed
CN-1330643-A IL-5 inhibiting azauracil pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2002-01-09 CN disclosed
CN-1261881-A 6-azauracil derivatives as IL-5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2000-08-02 CN disclosed
CN-1236366-A Amino acid ester-containing azole antifungal agents JANSSEN PHARMACEUTICA NV (BE) 1999-11-24 CN disclosed
CN-1041726-C 1.3-Dihydro-2H-Imidazo{4,5-6} Quinolin-2-One derivatives. JANSSEN PHARMACEUTICA NV (BE) 1999-01-20 CN disclosed
CN-1200122-A Lubeluzole N-oxide JANSSEN PHARMACEUTICA NV (BE) 1998-11-25 CN disclosed
CN-1148335-A Mucoadhesive emulsions containing cyclodextrins JANSSEN PHARMACEUTICA NV (BE) 1997-04-23 CN disclosed
CN-1136776-A Oral formulations of antifungal JANSSEN PHARMACEUTICA NV (BE) 1996-11-27 CN disclosed
CN-1072681-A 1,3-dihydro-2H-imidazo [4,5-b] quinoline-2-one-derivatives JANSSEN PHARMACEUTICA NV (BE) 1993-06-02 CN disclosed